TherapeuticsMD (TXMD) Cash from Financing Activities (2011 - 2023)

TherapeuticsMD has reported Cash from Financing Activities for 13 years, with the latest figure at $2.0 million in Q4 2023.

• For the quarter ending Q4 2023, Cash from Financing Activities rose 101.79% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2023 stood at -$108.2 million (up 54.0% YoY), and the FY2023 full-year result was $3.2 million, up 101.34% from the prior year.
• Cash from Financing Activities for Q4 2023 stood at $2.0 million, up from -$1000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $111.7 million in Q2 2019, with the low at -$120.0 million in Q2 2022.
• Historically, Cash from Financing Activities has averaged $9.2 million across 5 years, with a median of $890500.0 in 2021.
• Annual changes were most pronounced in 2020 — Cash from Financing Activities jumped 48669.82% — and 2022, when it tumbled 28137.38%.
• TherapeuticsMD's Cash from Financing Activities stood at $77.0 million in 2019, then slumped by 58.84% to $31.7 million in 2020, then tumbled by 95.73% to $1.4 million in 2021, then tumbled by 8373.84% to -$111.9 million in 2022, then soared by 101.79% to $2.0 million in 2023.
• The last three Cash from Financing Activities figures came in at $2.0 million (Q4 2023), -$1000.0 (Q3 2023), and -$111.9 million (Q4 2022), per Business Quant data.